Breaking News

Financial Report: Sanofi

April 29, 2014

Exchange rates hurt results

Sanofi

1Q Revenues: €7.8 billion (-3%)

1Q Earnings: €1.5 billion (-3%)

Comments: Diabetes revenue was up 13% to €1.7 billion. Genzyme revenues were up 22% to €566 million, driven by Aubagio with sales of €78 million versus €20 million in 1Q13. Consumer Healthcare sales were up 19% to €885 million. Sanofi Pasteur vaccine sales were €628 million, down 4%, reflecting a phasing effect in Pentaxim deliveries in Emerging Markets, offset by strong sales for Imovax in Japan and Menactra in the previous year period. Animal Health sales were down 2% to €517 million. Exchange rates had a negative effect of 6% in the quarter.
blog comments powered by Disqus
  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision

  • The Impact of Sample Handling  and Processing on the Outcome of Bioanalytical Testing

    The Impact of Sample Handling and Processing on the Outcome of Bioanalytical Testing

    Haiko Pillu, Head Technical Operations, Life Science Services, SGS Belgium NV||September 8, 2016
    Optimizing bioanalytical procedures to get reliable results in clinical studies

  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture